consisted of simply withholding warfarin and allowing the INR value to fall into the therapeutic range over a period of days. 1,2 However, a recent article 2 has highlighted the fact that patients with excessively elevated INR values are at high risk for both major and fatal bleeding, which confirms previous evidence 3, 4 suggesting that the risk of hemorrhage in patients receiving warfarin therapy is directly related to the degree of prolongation of the INR value. To guide therapy for patients with excessively elevated INR values, consensus statements recommend various interventions for these patients. 5 However, because few randomized controlled trials have evaluated the optimal treatment of such patients, these recommendations often are based on anecdotal clin-
D
espite careful monitoring, patients receiving warfarin therapy frequently present with asymptomatic elevations of their international normalized ratio (INR) above the desired range of values. The traditional management of such patients consisted of simply withholding warfarin and allowing the INR value to fall into the therapeutic range over a period of days. 1, 2 However, a recent article 2 has highlighted the fact that patients with excessively elevated INR values are at high risk for both major and fatal bleeding, which confirms previous evidence 3, 4 suggesting that the risk of hemorrhage in patients receiving warfarin therapy is directly related to the degree of prolongation of the INR value. To guide therapy for patients with excessively elevated INR values, consensus statements recommend various interventions for these patients. 5 However, because few randomized controlled trials have evaluated the optimal treatment of such patients, these recommendations often are based on anecdotal clin- ical experience or case series. To evaluate the current practices in the management of patients with elevated INR values, and to guide the design of future clinical trials in this area, we performed a physician survey in which physicians who regularly monitor warfarin anticoagulation (AC) were asked to provide treatment recommendations for six commonly encountered clinical scenarios involving patients with warfarin-associated coagulopathy.
Materials and Methods

Physician Survey
A survey was developed that described six clinical scenarios representing various combinations of INR values (range, 4.5 to 9.2), treatment setting (inpatient or outpatient), and the presence and severity of bleeding in patients receiving warfarin therapy. The survey was developed using an iterative process, in which the questions were reviewed and revised by content experts in thromboembolism in order to ensure that they were clear and would obtain reliable and reproducible data. Within the survey, each question presented the INR value and treatment setting explicitly but not the risk of bleeding or its severity. For each scenario (Table 1) , physicians were asked to select from a standardized list of management options (Table 2 ) or, if these were not acceptable, to provide an alternative treatment strategy. The demographic data collected included the physician's year of medical school graduation, practice setting (ie, teaching or community hospital), and frequency of supervision of patients receiving warfarin therapy (ie, frequently, infrequently, or not at all).
A cover letter also was developed and was mailed with each survey. The cover letter explained the reason for performing the study, that the identity of respondents would not be recorded or identifiable from the data set, and that the results of the survey would be collated and submitted for publication. Contact information also was provided so that the respondents could speak with the authors if they had additional questions or concerns about the project. The fact that the physicians' contact information had been obtained from the Canadian Society of General Internal Medicine also was explained in the cover letter.
To ensure a complete data set, a priori criteria were established to exclude incomplete or irrelevant surveys from the analysis. The exclusion criteria were the following: (1) the physician does not supervise patients who are receiving warfarin therapy or did not indicate the frequency of his or her supervision of those patients; (2) the physician no longer resides at the address provided; (3) the physician has retired from medical practice; or (4) the survey was returned incomplete (surveys with minor omissions such as not specifying practice setting were included).
Analysis
The analysis consisted of two parts: first, the proportion of respondents who selected each treatment option for the six scenarios was determined. Preferences for the route of administration and the dose of vitamin K also were determined. Second, the proportion of respondents who complied with the 1998 American College of Chest Physicians (ACCP) guidelines (see the Appendix) for the reversal of warfarinassociated coagulopathy was determined for each scenario.
Results
The survey was mailed in July 1999 to members of the Canadian Society of Internal Medicine who practice in Ontario, Canada, with a repeat mailing in October 1999 to physicians who had not responded to the first survey. In total, 201 surveys were mailed, and 120 were returned. Eighteen surveys were excluded for the following reasons: (1) the physician did not supervise patients who were receiving warfarin therapy (n ϭ 10); (2) the physician did not indicate the frequency of supervision of patients receiving warfarin therapy (n ϭ 3); (3) the physician had retired from medical practice (n ϭ 1); (4) the survey was returned incomplete (n ϭ 1); (5) the physician was deceased (n ϭ 1); or (6) the physician had moved and the current address could not be Hold warfarin therapy and administer vitamin K (oral, subcutaneous, or IV with dose specified by physician) without any other interventions 4
Hold warfarin therapy and administer vitamin K (oral, subcutaneous, or IV with dose specified by physician) and concurrent administration of either FFP or PCC 5
Hold warfarin therapy and administer either FFP or PCC 6
Other (physician asked to specify alternative treatment strategy) located (n ϭ 2). Thus, 102 surveys were included in the analysis. Of the respondents, 50 reported working in a teaching center, 51 reported working in a community hospital, and 68 frequently supervised warfarin therapy, while 34 infrequently supervised warfarin therapy.
Response to Surveys
Treatment preferences are presented in Table 3 . Scenarios 1, 2, 3, and 6 describe asymptomatic patients with INR values between 4.5 and 8.6. In these scenarios, the most frequent treatment selections were either the temporary withholding of warfarin therapy or the continuing of warfarin therapy at a reduced dose. In scenario 1, which described a patient with an INR of 8.6, 37% of respondents would administer vitamin K, whereas in the other three scenarios, which presented patients with INR values of 4.5 to 7.1, 1 to 12% of respondents would administer vitamin K. Scenarios 4 and 5 describe patients with elevated INR values and bleeding. In scenario 4, which described a patient with retinal bleeding, 71% of respondents would administer vitamin K, and 87% would administer some form of coagulation factor replacement (59% would administer it in concert with vitamin K). In scenario 5, which described a patient with hematuria, 82% of respondents would administer vitamin K, and 42% would administer some form of coagulation factor replacement (31% would administer it in concert with vitamin K) [comparison of the use of vitamin K, p ϭ 0.05; comparison for the use of coagulation factor replacement, p Ͻ 0.001].
With the exception of scenario 1, the most frequently selected route of vitamin K administration was subcutaneous (Table 3 ). There were no significant associations found when physician demographic characteristics were compared with the following three general categories of vitamin K use: vitamin K alone; vitamin K with fresh frozen plasma (FFP) or prothrombin complex concentrate (PCC); and no vitamin K (data not shown).
Compliance With ACCP Guidelines
Scenarios 3 and 6, describing patients with asymptomatic INR values of Ͻ 5.0, were most appropriately treated by recommendation 1 of the ACCP guidelines (see the Appendix). The treatment recommendation was followed by 99% and 96% of respondents, respectively. Scenarios 1 and 2, describing patients with INR values between 5.0 and 9.0 without bleeding, were best treated by recommendation 2 in the ACCP guidelines. In scenario 1, 62% of respondents complied with the recommended treatment, while 86% of respondents complied with the recommended treatment for scenario 2. Scenario 5 presents a patient best treated following recommendation 3 (INR, Ͼ 9.0 without serious bleeding), and 1% of respondents treated this patient, as recommended, with oral vitamin K therapy alone. If the hematuria reported in this case is regarded as serious bleeding, 9% of respondents treated the patient as recommended in recommendation 4. The retinal bleeding described in scenario 4 satisfies the condition of serious bleeding and should be treated as recommended by recommendation 4. Only 10% of respondents followed the guideline and administered 10 mg IV vitamin K (with 9% selecting vitamin K administration in addition to FFP or PCC, and 1% selecting vitamin K administration alone).
Discussion
In this survey, we determined physician preferences for the management of patients with excessive warfarin-associated AC. First, there are two major findings from this survey. Vitamin K was used more frequently than had been reported previously in case series of patients with high INR values, 1, 6, 7 and the most frequently selected route of vitamin K administration was the subcutaneous route. Second, compliance with the ACCP guidelines for treatment of warfarin-associated coagulopathy was poor (in some cases Ͻ 10%).
Our results suggest that general internists in Ontario are aware that vitamin K therapy is a safe and effective method for reversing warfarin-induced excessive AC; however, the variety of routes and doses selected by respondents highlights the inconsistency with which patients are treated with vitamin K. This is noteworthy because the inappropriate use of vitamin K therapy, particularly in excessive doses, may be more hazardous than the lack of vitamin K use. Across the six scenarios, 6% of all respondents who selected vitamin K therapy chose doses of 20 to 25 mg, doses that could result in "overcorrection" of the INR, placing the patient at risk of thromboembolic complications. It is also noteworthy that physicians preferred the subcutaneous route of vitamin K administration, a route that is less effective in reestablishing a therapeutic level of AC than the IV route. 8, 9 Evidence-based guidelines for the clinical management of patients with warfarin-induced excessive AC are available from the ACCP. 5, 10 The treatment recommendations for the reversal of excessive warfarin AC are graded C2, indicating that the studies used to formulate these guidelines were observational in nature. These guidelines suggest the advisability of administration of oral vitamin K to patients with INRs Ͼ 5.0. However, the actual frequency with which oral vitamin K therapy is administered to such patients is unknown. Previous reported rates of oral vitamin K therapy have been low, ranging between 5% and 20%. 1, 6, 7 Despite the relatively frequent use of vitamin K in the scenarios presented in this survey, compliance with ACCP recommendations specifying the appropriate dose and route of vitamin K was considerably lower. The disparity between vitamin K usage and ACCP compliance is highlighted by scenario 5, which described painless hematuria. The greatest proportion of respondents selected vitamin K therapy for this scenario (82%), but only 1% of respondents complied with the ACCP guidelines with respect to dose and route of administration.
There are several characteristics that support the validity and generalizability of the findings of this survey. First, the treatment options presented in the survey are likely a valid representation of the usual clinical practice, as these options were selected by 96% and 100% of respondents, depending on the scenario. Second, approximately two thirds of respondents frequently supervised patients receiving warfarin therapy, and physicians who did not supervise such patients were excluded from the analysis. Finally, the response rate to the survey was 59%, which is consistent with the response rate seen in other physician surveys dealing with anticoagulant management. [11] [12] [13] The primary limitation of the survey results is that they reflect self-reported, and not confirmed, management approaches.
In summary, our survey suggests that there is considerable variability in the management of patients with excessive warfarin-associated AC. The lack of widely accepted treatments for this problem reaffirms the need for randomized controlled trials to compare the efficacy of different routes of administration of vitamin K for warfarin-associated coagulopathy.
